Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
Billionaire health-care investor Phillip Frost charged by SEC with pump-and-dump schemes - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva earnings preview: Opioid suits are 'key' - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva: Another Day, Another Downgrade - Barron's
Teva to pay $225M to settle cholesterol drug price-fixing charges
Teva shares surge on corporate shake-up - MarketWatch
Teva Pharmaceuticals - Wikipedia
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceutical Is in Recovery - WSJ
Teva Can Reach $100 on Allergan Unit Acquisition - Barron's
Teva's new plan is to raise drug prices, but it won't be easy - MarketWatch
Teva's Austedo, Ajovy sales offset Q4 declines in generics
Teva shares climb as third-quarter sales top estimates - MarketWatch
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva to lay off 14,000 workers in bid for survival — but some are skeptical - MarketWatch
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Israeli stocks slump in first day of trade since Gaza attack - MarketWatch
Teva Reports Growth in Fourth Quarter and Full Year 2023
TEVA: A Pharma Stock to Watch | Mish's Market Minute | StockCharts.com
Teva shares climb as third-quarter sales top estimates - MarketWatch
